Carolina D. Weller, Anna Barker, Ian Darby, Terrence Haines, Martin Underwood, Stephanie Ward, Pat Aldons, Elizabeth Dapiran, Jason J. Madan, Paula Loveland, Sankar Sinha, Mauro Vicaretti, Rory Wolfe, Michael Woodward, John McNeil
Abstract
Venous leg ulceration is a common and costly problem that is expected to worsen as the population ages. Current treatment is compression therapy; however, up to 50 % of ulcers remain unhealed after 2 years, and ulcer recurrence is common. New treatments are needed to address those wounds that are more challenging to heal. Targeting the inflammatory processes present in venous ulcers is a possible strategy. Limited evidence suggests that a daily dose of aspirin may be an effective adjunct to aid ulcer healing and reduce recurrence. The Aspirin in Venous Leg Ulcer study (ASPiVLU) will investigate whether 300-mg oral doses of aspirin improve time to healing.
This randomised, double-blinded, multicentre, placebo-controlled, clinical trial will recruit participants with venous leg ulcers from community settings and hospital outpatient wound clinics across Australia. Two hundred sixty-eight participants with venous leg ulcers will be randomised to receive either aspirin or placebo, in addition to compression therapy, for 24 weeks. The primary outcome is time to healing within 12 weeks. Secondary outcomes are ulcer recurrence, wound pain, quality of life and wellbeing, adherence to study medication, adherence to compression therapy, serum inflammatory markers, hospitalisations, and adverse events at 24 weeks.
The ASPiVLU trial will investigate the efficacy and safety of aspirin as an adjunct to compression therapy to treat venous leg ulcers. Study completion is anticipated to occur in December 2018.
Australian New Zealand Clinical Trials Registry, ACTRN12614000293662.
Pharmacology, Toxicology and Pharmaceutical Science
5
5%
Biochemistry, Genetics and Molecular Biology
4
4%
Agricultural and Biological Sciences
3
3%
Other
10
9%
Unknown
35
32%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2017.
All research outputs
#17,154,245
of 25,986,827 outputs
Outputs from Trials
#23
of 45 outputs
Outputs of similar age
#186,230
of 317,735 outputs
Outputs of similar age from Trials
#47
of 70 outputs
Altmetric has tracked 25,986,827 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 45 research outputs from this source. They receive a mean Attention Score of 5.0. This one scored the same or higher as 22 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,735 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
